Search
for
Sort by
Research 271–300 of 1000+
- Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
- JAK Inhibitors for Treatment of Alopecia Areata
- Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention
- Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses
- JAK inhibitors and alopecia areata
- Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata
- Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
- Treatment of pediatric alopecia areata: A systematic review
- Pathomechanisms of immune-mediated alopecia
- Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
- Tofacitinib for the treatment of alopecia areata in preadolescent children
- Transient Efficacy of Tofacitinib in Alopecia Areata Universalis
- Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
- The Diagnosis and Treatment of Hair and Scalp Diseases
- Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
- New drugs under investigation for the treatment of alopecias
- Treating Alopecia Areata: Current Practices Versus New Directions
- Treatment of severe alopecia areata with baricitinib
- Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
- Shared Decision-Making, Therapeutic Choice, and Decisional Regret in Patients With Alopecia Areata
- Lack of efficacy of apremilast in 9 patients with severe alopecia areata
- Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient
- Current Treatments for Alopecia Areata
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Emerging drugs for alopecia areata: JAK inhibitors
- Novedades terapéuticas en tricología
- The role of oclacitinib in the management of ischaemic dermatopathy in four dogs
- Treatments options for alopecia
- Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series